Hexaxim

Each 0.5 mL Diphtheria toxoid not <20 IU; tetanus toxoid not <40 IU; Bordetella pertussis antigens: Pertussis toxoid 25 mcg, filamentous haemagglutinin 25 mcg; inactivated poliovirus: Type 1 (Mahoney) 40 D-antigen u, type 2 (MEF-1) 8 D-antigen u, type 3 (Saukett) 32 D-antigen u; HBsAg 10 mcg; HIB polysaccharide 12 mcg (polyribosylribitol phosphate), conjugated to tetanus protein 22-36 mcg

Primary & booster vaccination of infants & toddlers from 6 wk to 24 mth against DPT, hepatitis B, poliomyelitis & invasive diseases caused by HIB.

IM Primary vaccination 3 doses of 0.5 mL at least 4-wk interval & as per schedules 6, 10, 14 wk; 2, 3, 4 mth; 3, 4, 5 mth; 2, 4, 6 mth or 2 doses of 0.5 mL at least 8-wk interval & as per schedule 3, 5 mth. Booster vaccination At least 6 mth after last priming dose.

History of anaphylactic reaction. Hypersensitivity to active substances, trace residual (glutaraldehyde, formaldehyde, neomycin, streptomycin & polymyxin B), any pertussis vaccine or after previous administration or vaccine containing same components or constituents. Encephalopathy of unknown aetiology w/in 7 days following prior vaccination w/ pertussis-containing vaccine (whole cell or acellular pertussis vaccines). Uncontrolled neurological disorder or epilepsy.

Not to be administered by intravascularly, intradermally or SC. Not for prevention of diseases caused by pathogens other than Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, HBV, poliovirus or HIB nor for protection against infection by other agents eg, HAV, HCV, hepatitis E virus or other liver pathogens; other types of H. influenzae or meningitis of other origins. Postpone immunization in patients w/ moderate to severe acute febrile illness or infection. Temp ≥40°C, collapse or shock-like state & persistent, inconsolable crying lasting ≥3 hr w/in 48 hr of vaccination; convulsions w/ or w/o fever occurring w/in 3 days of vaccination. History of febrile convulsions or Sudden Infant Death Syndrome; Guillain-Barre syndrome or brachial neuritis; thrombocytopenia or bleeding disorder; immunosuppressive treatment or immunodeficiency; impaired hepatitis B response; phenylketonuria. Resp monitoring for 48-72 hr in very premature infants (≤28 wk of gestation) & w/ previous history of resp immaturity. Interference w/ lab urine test. Chronic renal failure. Not intended for women of childbearing age. Pregnancy & lactation. Childn >24 mth.

Anorexia; crying, somnolence; vomiting; inj site pain, erythema, swelling, irritability, pyrexia. Abnormal crying, diarrhoea; inj-site induration.

Interference in Ab response w/ varicella vaccine. Not to be mixed w/ any other vaccines or other parenterally-administered medicinal products.

Vaccines, Antisera & Immunologicals

J07CA09 - diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B ; Belongs to the class of combined bacterial and viral vaccines.

S